By: Kristi Rosa
Key opinion leaders in the field share what they considered to be the greatest takeaways from the 2020 Genitourinary Cancers Symposium and provide insight on where treatment is headed in their respective areas of expertise.
By: Wayne Kuznar
Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma; however, the combination did not meet the primary endpoint of overall response rate.
By: Gina Columbus
Enfortumab vedotin-ejfv combined with pembrolizumab led to an objective response rate of 73% in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy.